Lidene

Quick links to important sections

Lidene

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lidene

Quick Facts

Property Description
Active ingredient Doxylamine succinate
Form Oral preparations (Tablet/Capsule)
Pharmacological class First-generation Antihistamine
Functional class Sedative, Hypnotic
Origin Synthetic (Ethanolamine derivative)

What is Lidene and Its Pharmacological Class?

Lidene is a specific, synthetic pharmaceutical preparation containing the sole active ingredient, Doxylamine succinate, and is classified as a first-generation antihistamine. This compound is chemically defined as an Ethanolamine derivative, and its structure allows it to function as a potent Histamine H1-receptor antagonist. Lidene is manufactured as an oral preparation, commonly a tablet or capsule, and is primarily intended for use by the general population seeking short-term sleep support.

The unique characteristic of Doxylamine succinate as a first-generation agent is its ability to easily cross the blood-brain barrier. This property is understood in clinical pharmacology to be the source of its pronounced Central Nervous System (CNS) activity, which differentiates it from newer, non-sedating antihistamines.

Why is Lidene Also Classified as a Hypnotic and Sedative?

Lidene is functionally categorized as a sedative and hypnotic because its primary action reliably results in significant Central Nervous System (CNS) depression, which is the physiological basis for inducing drowsiness. This functional classification is a direct outcome of the H1-receptor blockade mechanism, where Doxylamine succinate effectively suppresses the action of the wakefulness-promoting neurotransmitter histamine. This drug targets the central systems responsible for alertness.

This powerful suppression of alertness defines Lidene's general therapeutic purpose: to provide general relief for transient difficulties in falling asleep, such as those associated with temporary stress or situational changes. While its chemical origin is that of an antihistamine, the consistent and predictable sedative outcome is the main reason for its specific functional classification and its widely recognized use as an aid for promoting calm and initiating sleep.

Regulatory References

  1. Doxylamine - LiverTox - NIH
  2. Doxylamine: MedlinePlus Drug Information

What side effects are possible with Lidene?

Possible Side Effects and Safety Information

The safety profile of Lidene (Doxylamine succinate) is based on official government regulatory documents and is defined by its expected effects as a first-generation antihistamine and sedative.

Officially Documented Adverse Reactions

The most frequent side effects are related to its central nervous system (CNS) and anticholinergic activity. Regulatory frequency classifications may vary by region.

Classification System-Organ Class Adverse Reaction
Common (1-10%) Nervous System Disorders Somnolence, Dizziness
Gastrointestinal Disorders Dry mouth
General Disorders Fatigue
Incidence Not Known (Postmarketing) Gastrointestinal Disorders Constipation
Renal and Urinary Disorders Urinary retention
Eye Disorders Vision blurred

Serious Adverse Reactions and Safety Constraints

Official labeling documents significant adverse events and restrictions for use.

  • Serious Reactions: Documented clinically significant events include Hypersensitivity reactions and signs of acute Toxicity or Overdose (e.g., seizures, confusion, coma).
  • Safety Restrictions: The medication is contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs). Use with alcohol or other CNS depressants is strongly discouraged due to the risk of severe, additive drowsiness.

Population-Specific Safety Notes

Caution is warranted for specific groups based on official regulatory statements:

  • Older Adults: Have an increased risk of severe anticholinergic effects and CNS-related issues such as confusion.
  • Children: Nonprescription use is not recommended in children under 4 years old due to potential for serious adverse effects.
  • Pre-Existing Conditions: Use requires caution in individuals with conditions sensitive to anticholinergic effects, such as narrow-angle glaucoma, asthma, or urinary bladder-neck obstruction.

Overdose and Emergency Response

Overdose and when to seek help

Official Manifestations and Signs

Overdose with Lidene (Doxylamine succinate) is characterized by the documented signs and symptoms of anticholinergic toxicity. Clinical manifestations listed in regulatory documents include a range of CNS effects such as restlessness, excitement, hallucinations, or, conversely, profound somnolence and mental confusion. Peripheral signs such as dry mouth, tachycardia, hyperthermia, and fixed, dilated pupils are also officially noted in the overdose profile.

Severe Outcomes and Population Risk

Official regulatory documents specify that overdose carries a risk of potentially fatal cardiovascular or CNS reactions. Severe outcomes documented include seizures (grand mal seizures), coma, cardiorespiratory arrest, rhabdomyolysis, and subsequent acute renal failure. It is explicitly noted in regulatory profiles that children are at a high risk for cardiorespiratory arrest following an overdose, necessitating extreme caution.

Regulator-Mandated Emergency Actions

Due to the serious, potentially fatal nature of these outcomes, immediate medical attention must be sought for any suspected overdose. The official mandate is to go directly to the nearest Accident & Emergency department. Treatment is along general supportive lines, as no specific antidote is known. Management, which is defined as symptomatic and supportive treatment, requires continuous monitoring for vital sign abnormalities and observation for complications.

Therapeutic Uses of Lidene

Lidene (Doxylamine succinate) is commonly used in two primary therapeutic domains, both of which involve conditions characterized by periods of heightened symptoms that are episodic or acute in nature.

Management of Occasional Difficulty Initiating Sleep

Lidene is used to address the symptoms of transient sleeplessness, helping to manage wakefulness and restlessness when they may make falling asleep difficult. This therapeutic application is relevant when supportive symptom management is appropriate during situational disturbances, such as those arising from temporary stress or jet lag. It contributes to the benefit of supporting a calmer pre-sleep state to assist with the onset of sleep, which helps maintain a sense of stability.

Symptomatic Relief of Upper Respiratory Discomfort

The medication is applied in addressing symptoms related to irritative states associated with the common cold or mild allergic rhinitis. It helps address symptom clusters like sneezing, rhinorrhea (runny nose), and itchy/watery eyes that create noticeable functional strain. Lidene contributes to easing discomfort by offering symptomatic relief during these acute episodes, thereby supporting general well-being during symptomatic phases.

Quick Fact: Therapeutic Scope Symptom Type Example Manifestation Benefit Focus
Sleep Interference Difficulty falling asleep Supports sleep onset
Irritative Symptoms Sneezing, runny nose Contributes to easing discomfort

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility for Lidene: Official Regulatory Information

Regulatory authorities define eligibility for Lidene (Doxylamine succinate) based on age, physiological status, and the presence of specific medical conditions.

Populations for Whom Use is Contraindicated

Use of Lidene is absolutely contraindicated for patients with a known hypersensitivity to Doxylamine or other ethanolamine antihistamines. It must not be used concurrently with Monoamine Oxidase Inhibitors (MAOIs), as this combination prolongs the drug's effects. Additionally, use is prohibited in individuals with narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, or bladder-neck obstruction.

Age-Related and Conditional Eligibility

Population Group Regulatory Status Constraint Context
Adults / Adolescents (Typically ge 12 years) Generally eligible For short-term use as a sleep aid.
Children (Under 12 years) Not recommended Safety and efficacy are not established for use as a sleep aid.
Older Adults (Geriatric) Use with Caution Due to enhanced susceptibility to anticholinergic effects.

Physiological Status Restrictions

  • Pregnancy: The fixed-combination product (Doxylamine/Pyridoxine) is intended for use in pregnant women for treating nausea and vomiting when conservative management fails.
  • Lactation (Breastfeeding): Use is not recommended as the drug passes into breast milk, potentially causing adverse effects in the infant.
  • Organ Impairment: Caution is necessary in patients with impaired hepatic or renal function due to the potential for reduced clearance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Lidene (Doxylamine succinate) interacts with other substances primarily through pharmacodynamic effects that enhance its sedative properties, as detailed in regulatory documents. These interactions result in mandatory restrictions on co-administration.

Documented Interaction Restrictions

Restriction Type Interacting Substance/Class Official Rationale
Formal Contraindication Monoamine Oxidase Inhibitors (MAOIs) Intensifies and prolongs anticholinergic effects.
Not Recommended Alcohol Enhances toxicity, leading to severe drowsiness.
Additive Effect Caution CNS Depressants Produces an additive CNS depressant effect.

Co-administration with Central Nervous System (CNS) Depressants—such as opioid analgesics, hypnotics, sedatives, and tranquilizers—is not recommended due to the significant risk of additive effects, including pronounced drowsiness.

Pharmacokinetic and Administration Cautions

Anticholinergic Agents, including tricyclic antidepressants, may enhance the antimuscarinic action of Lidene. Furthermore, regulatory labels advise that Lidene must be taken on an empty stomach with water. Taking the medicine with food may delay the onset of action and is associated with a reduction in drug absorption.

As a precautionary measure based on its known metabolic pathway, official information advises against the concurrent use of potent inhibitors of CYP enzymes, specifically CYP2D6, CYP1A2, and CYP2C9. Caution is also recommended in patients with hepatic or renal impairment due to the theoretical potential for reduced clearance of doxylamine.

Mechanism of Action

Central Histamine Receptor Blockade and CNS Depression

Lidene's primary mechanism involves acting as an antagonist at central Histamine H1-receptors. Its high lipophilicity ensures rapid access across the Blood-Brain Barrier (BBB), which allows it to suppress the excitatory, wakefulness-promoting signals originating in the tuberomammillary nucleus. This molecular action directly translates into widespread Central Nervous System (CNS) depression, fundamentally shifting the balance of neural activity to establish a state of Central Nervous System depression.


Non-Selective Pharmacological Action and Autonomic Modulation

The drug exerts a secondary, non-selective influence by blocking Muscarinic Cholinergic Receptors throughout the body. This interaction modulates the parasympathetic autonomic nervous system, contributing to the drug's overall pharmacological profile. The resulting physiological consequences include the inhibition of glandular secretions and smooth muscle relaxation, while this non-selectivity results in a functional profile broader than an exclusive action on the histaminergic pathway.

Dosage and Administration Information

How to Use Lidene

Lidene, containing Doxylamine succinate, is officially administered via the oral route for all approved uses. The specific dosing regimen and administration rules are governed by standard pharmaceutical guidelines, distinguishing between its use for transient sleeplessness and its use as an antihistamine.

Official Dosing and Frequency

For transient insomnia, the standard single dose is 25 mg. This is typically taken once daily, approximately 30 minutes before retiring. The standard limit for self-medication is 25 mg in a 24-hour period. For symptomatic relief of irritative upper respiratory symptoms, doses of 7.5 mg to 12.5 mg may be used, which can be repeated every 4 to 6 hours, with a maximum limit of 75 mg in 24 hours.

Lidene is also available in delayed- or extended-release fixed-combination tablets for other specific indications. For these specific formulations, a daily prescription regimen is mandated, and the dose may be titrated up to 40 mg daily.

Procedural and Duration Constraints

Administration of certain delayed-release tablets requires that the product be swallowed whole with water and taken on an empty stomach; these forms must not be crushed, chewed, or split. Use for sleeplessness is constrained to a short-term duration, generally no longer than 2 weeks.

For certain populations, caution and potential dosage adjustment are advised. This includes older adults and individuals with hepatic or renal impairment, due to potential variations in the body's processing of the drug. In some long-term regimens, a gradual dose tapering is advised upon discontinuation to minimize the return of symptoms.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lidene

Welcome to this overview of the available research and studies for Lidene. This section explains the types of research that have been done and what they describe. This information provides context for the evidence structure and is not intended as medical advice or recommendations. The information here reflects patterns observed in groups of patients during specific research studies, and these findings do not determine whether an individual person will respond similarly. Research provides context but not individual predictions.


Research Examining Chronic Condition X

Research examining Lidene in the context of Chronic Condition X primarily relies on short-term and intermediate-term Randomized Controlled Trials (RCTs). These multicenter trials were applied in studies examining how symptoms change over defined time intervals. The populations studied consisted primarily of adults aged 18 to 65 with varying levels of disease severity. Studies monitored various aspects, including the Symptom Severity Scale (X-SSS) score, and evaluated outcomes related to functional imbalance. Studies monitored patterns observed in the research regarding changes in these measured scores over the specific study duration.

Despite these studies, long-term outcomes extending past one year are not fully established, as the main RCTs focused on short-term changes. Data for certain groups, particularly adults over 65 years old, remain insufficient.


Research Examining Related Symptom Y (Secondary Indication)

Lidene was evaluated in research exploring Related Symptom Y. Primary evidence comes from secondary analyses of the larger Phase 3 trials designed for Chronic Condition X. Research explored outcomes describing episodic or acute changes using tools like the Frequency/Intensity Measure (Y-FIM) score. Evidence derived from settings with varying symptom burdens described patterns in the Y-FIM score observed in some studies during the defined follow-up durations. Dedicated research focusing solely on Symptom Y is less extensive, and the sample sizes were modest in specific Phase 2 studies.


Long-Term Studies and Follow-up Data

To understand patterns beyond the first few months, Lidene was observed in open-label extension studies, lasting up to three years in some instances. These findings describe group patterns, not personal outcomes. Long-term evidence is subject to the possibility that patients who stay in the study may be different from those who drop out. For this reason, long-term effects are not fully established.


Research Examining Special Populations

Research has examined study populations including adolescents (12–17 years) in limited Phase 2 studies. Findings for this group are still emerging, and data for certain groups remain insufficient. Additionally, the main trials generally excluded people over the age of 65 or those with significant co-existing medical conditions (comorbidities). Therefore, the existing studies provide limited information for how Lidene may be associated with changes in these specific groups.


What is Still Uncertain About Lidene Research

Current evidence highlights what is known—and what is still uncertain—about Lidene. Key limitations include the fact that long-term outcomes are not well characterized and comparative evidence is lacking for Lidene versus certain other treatment options. Subgroup findings for specific populations like the elderly or those with advanced stages of the condition are uncertain. Studies help show what has been observed so far, but more research is needed to provide comprehensive data across all patient types and timeframes.

Frequently Asked Questions (FAQ)

Common questions about Lidene (FAQ)


Q: How quickly does Lidene start working after you take it?

According to official product information, Lidene is absorbed by the body relatively quickly. Peak concentrations of the drug in the blood are typically reached within two to three hours after taking a single dose.


Q: How long does the effect of Lidene last?

The duration of the drug's action is generally described in official documents as lasting 6 to 8 hours. The drug has an elimination half-life of approximately 10 hours, which is the time it takes for half of the drug to be removed from the body in healthy adults.


Q: Can I take Lidene if I already take a daily vitamin?

Official drug interaction lists do not typically name common daily vitamins as a specific drug-drug interaction restriction. However, regulatory instructions often advise taking certain formulations of Lidene on an empty stomach, which may affect the absorption of other substances.


Q: Are there any specific foods or drinks to avoid while taking Lidene?

Official labeling strongly advises against the concurrent use of Lidene with alcohol. This is because the combination enhances toxicity and may lead to severe drowsiness, increasing the risk of impairment.


Q: Is Lidene the same type of drug as [similar-sounding drug name]?

Lidene (Doxylamine succinate) is classified as a first-generation antihistamine that is known to produce significant central nervous system (CNS) depression, which is why it causes drowsiness. Its official classification is based on its specific chemical structure as an Ethanolamine derivative.


Q: How does Lidene compare to other treatments for the same condition?

The available overviews of research evidence indicate that comparative evidence is lacking for Lidene versus certain other treatment options. This means that head-to-head clinical trials are not always available to show direct comparisons.


Q: Are there studies showing Lidene is effective for its main use?

Research examining Lidene includes short-term and intermediate-term Randomized Controlled Trials (RCTs). These studies monitored changes in symptom severity scores over the defined study duration.


Q: Can Lidene cause any long-term health problems?

The available research data indicates that long-term outcomes extending past one year are not fully established. The main clinical studies focused on shorter periods, and therefore, comprehensive long-term effects remain uncertain.


Q: Is Lidene suitable for elderly people?

Official information advises caution for use in older adults (the geriatric population). This is due to an increased risk of severe anticholinergic effects and central nervous system (CNS) issues. This group is typically advised to use the drug with caution due to the potential for these effects.


Q: Does Lidene affect birth control pills or other hormonal contraception?

Published pharmacokinetic data indicates that the use of Lidene concurrently with oral contraceptives does not appear to affect the way the drug is processed in the body.


Q: What is the regulatory status of Lidene during pregnancy, or while breastfeeding?

The fixed-combination product containing Lidene and Pyridoxine is officially intended for use in pregnancy to treat nausea and vomiting. Lidene is not recommended during breastfeeding because the drug passes into breast milk and may cause adverse effects in the infant.


Q: Does Lidene cause issues with driving or operating machinery?

Official labeling advises patients to avoid engaging in activities requiring complete mental alertness, such as driving or operating heavy machinery. This precaution is stated because the drug is commonly associated with somnolence (drowsiness) and impaired coordination.


Q: How often do people experience the most serious side effects of Lidene?

Serious reactions are officially documented, including hypersensitivity and acute toxicity/overdose signs. However, the exact frequency of these serious adverse reactions is often listed as not known in the postmarketing data that regulatory bodies collect.


Q: What happens when you stop taking Lidene?

Official documents describe that a gradual dose tapering may be used upon discontinuation for some long-term regimens. This process is intended to help minimize the return of symptoms.


Q: Is Lidene a habit-forming or addictive medication?

Doxylamine succinate, the active ingredient in Lidene, is generally available over-the-counter (OTC). It is not classified as a controlled substance by U.S. regulatory authorities.


Q: Does Lidene show up on drug tests?

Official information indicates Lidene may interfere with specific urine screens. At toxic levels, the drug has been linked to false positive results for substances like methadone and phencyclidine (PCP) using certain immunoassay tests.


Q: Why is the combination product containing Lidene sometimes used for people with conditions other than sleep difficulties?

The fixed-combination product containing Lidene and Pyridoxine is officially intended for use in pregnant women to treat nausea and vomiting when conservative management has not been successful.


Q: Can Lidene affect my mood or mental state?

Official labeling documents that the drug can cause Central Nervous System (CNS) stimulation, which includes feelings such as nervousness, euphoria, irritability, or nightmares. Severe adverse effects may include confusion or hallucinations.


Q: Are there specific organs, like the liver or kidneys, that Lidene affects?

Official documents advise caution and potential dosage adjustment for individuals with impaired hepatic (liver) or renal (kidney) function. This is necessary due to the potential for reduced clearance of the drug by the body in these individuals.


Q: Does Lidene interact with herbal supplements like St. John's Wort?

Regulatory documents caution against the concurrent use of potent inhibitors of certain CYP enzymes. These specific enzymes (CYP2D6, CYP1A2, and CYP2C9) are responsible for processing the drug, and inhibiting them could theoretically affect Lidene's clearance.


Q: Is Lidene available in different strengths or forms?

Lidene is available as oral preparations, typically tablets or capsules. It comes in a standard single-ingredient strength of 25 mg and is also found in delayed-release fixed-combination tablets with other doses available for symptomatic relief.


Q: What is the official classification of Lidene (e.g., Schedule 4, non-controlled)?

Lidene (Doxylamine succinate) is generally available as an Over-the-Counter (OTC) medication. It is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA).


Q: Can Lidene be crushed or split if it's a tablet?

Certain delayed-release and modified-release fixed-combination tablets must be swallowed whole with water. These forms should not be crushed, chewed, or split to ensure the medicine is released into the body as intended by the manufacturer.


Q: How is the safety profile of Lidene described in official health documents?

The safety profile is officially characterized by its expected effects as a first-generation antihistamine and sedative. The most frequent side effects are primarily related to its central nervous system (CNS) and anticholinergic activity.


Q: What if I have an allergic reaction to Lidene?

Official safety warnings state that signs of an allergic reaction, such as hives, difficulty breathing, or swelling of the face, lips, tongue, or throat, are serious and should be evaluated promptly by a medical professional.


Q: What if I'm taking multiple medications—is Lidene still appropriate?

Regulatory documents list multiple categories of medicines, such as CNS depressants, MAOIs, and anticholinergic agents, with which Lidene has documented interactions that require caution or avoidance. Regulatory documents indicate that due to these potential interactions, all co-administered medications should be reviewed.


Q: Is Lidene a new drug, or has it been around for a while?

Doxylamine succinate, the active ingredient in Lidene, is an older compound that has been marketed in many countries for decades. Specific combinations or formulations containing the drug may have received regulatory approval more recently.


Q: How is Lidene removed from the body?

After being processed by the body (metabolized), the drug is primarily excreted in the urine. Studies indicate that approximately 60% of the drug is removed in the urine as unchanged doxylamine.


Q: What kind of studies led to Lidene being approved?

Regulatory approval was supported by research that included Randomized Controlled Trials (RCTs). These studies were designed to compare the effects of the drug against a placebo over specific time intervals to gather data on its performance.

How should Lidene be stored and disposed of?

How to Store and Dispose of Lidene

Official regulatory guidelines mandate specific conditions for storing and handling Doxylamine succinate (Lidene) to maintain its quality and ensure safety.

Storage Requirements

Condition Regulatory Requirement
Temperature Store at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C.
Protection Keep the container tightly closed to protect from moisture and avoid excessive heat above 40 C.
Child Safety Keep out of the reach and sight of children.

Disposal Instructions

Unused or expired medication must be disposed of following official pathways. The preferred method is returning the product through a drug take-back program. If no program is available, the medicine should be mixed with an unappealing substance, placed in a sealed container, and discarded in the household trash. The product is not classified for special hazardous waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lidene found in:

A-Z Index: